EUR 2.66
(1.33%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -3.35 Million EUR | 20.76% |
2022 | -4.23 Million EUR | 9.72% |
2021 | -4.68 Million EUR | -37.87% |
2020 | -3.39 Million EUR | 0.0% |
2019 | - EUR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | 107.17 Thousand EUR | 110.04% |
2024 Q3 | -1.37 Million EUR | -1386.72% |
2024 Q1 | -1.14 Million USD | 38.02% |
2023 Q4 | -1.72 Million EUR | -62.14% |
2023 FY | -3.35 Million EUR | 20.76% |
2023 Q3 | -1.06 Million EUR | -200.14% |
2023 Q2 | 1.06 Million EUR | 165.28% |
2023 Q1 | -1.62 Million EUR | 0.0% |
2022 Q4 | - EUR | 0.0% |
2022 FY | -4.23 Million EUR | 9.72% |
2021 FY | -4.68 Million EUR | -37.87% |
2020 FY | -3.39 Million EUR | 0.0% |
2019 FY | - EUR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Atrys Health, S.A. | -45.59 Million EUR | 92.645% |
Biotechnologies Assets SA | 1.57 Million EUR | 313.052% |
Pharma Mar, S.A. | 1.13 Million EUR | 394.894% |
Laboratorios Farmaceuticos Rovi, S.A. | 170.33 Million EUR | 101.968% |